Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist

1990 ◽  
Vol 149 (5) ◽  
pp. 308-313 ◽  
Author(s):  
W. Oostdijk ◽  
R. Hümmelink ◽  
R. J. H. Odink ◽  
C. J. Partsch ◽  
S. L. S. Drop ◽  
...  
Keyword(s):  
Precocious Puberty ◽  
Slow Release ◽  
Central Precocious Puberty ◽  
Gonadotropin Releasing Hormone ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist

scholarly journals Autoimmune thyroiditis after long term gonadotropin- releasing hormone agonist treatment for central precocious puberty: case report

2020 ◽  
Vol 12 (1) ◽  
pp. 62-65
Author(s):  
Maja Tankoska ◽  
Avdi Murtezani ◽  
Konstandina Kuzevska-Maneva ◽  
Marina Krstevska – Konstantinova
Keyword(s):  
Thyroid Gland ◽  
Thyroid Function ◽  
Precocious Puberty ◽  
Autoimmune Thyroiditis ◽  
Central Precocious Puberty ◽  
Gonadotropin Releasing Hormone ◽  
Thyroid Antibodies ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist

There is a small number of studies that have reported abnormalities in endocrine function after a long-term gonadotropin-releasing hormone agonist (GnRHa) treatment in girls. This treatment is considered as safe and effective by most authors. We report our second case of unusual outcome of long-term GnRHa therapy in a girl with central precocious puberty (CPP) of idiopathic or familial etiology. She has received monthly depot of injections of triptorelin for a time period of 4 years. We have examined thyroid function by measuring serum levels of thyrotropin (TSH), thyroxine (T4), thyroid antibodies and ultrasound of thyroid gland. At the age of 11 years she developed a mild goiter and presented with autoimmune thyroiditis, having elevated thyroid antibodies and ultrasound of thyroid gland typical for Hashimoto thyroiditis. Having in mind these two cases, we suggest a closer monitoring of thyroid function in girls with CPP, before and during therapy with GnRH agonist.

Sign in / Sign up

Export Citation Format

Share Document